- Home
- LODE vs MGNX Comparison
LODE vs MGNX Comparison
Compare LODE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- MGNX
- Stock Information
- Founded
- LODE 2008
- MGNX 2000
- Country
- LODE United States
- MGNX United States
- Employees
- LODE N/A
- MGNX N/A
- Industry
- LODE Major Chemicals
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- LODE Industrials
- MGNX Health Care
- Exchange
- LODE Nasdaq
- MGNX Nasdaq
- Market Cap
- LODE 119.2M
- MGNX 99.7M
- IPO Year
- LODE N/A
- MGNX 2013
- Fundamental
- Price
- LODE $3.77
- MGNX $1.76
- Analyst Decision
- LODE Hold
- MGNX Hold
- Analyst Count
- LODE 1
- MGNX 6
- Target Price
- LODE $4.00
- MGNX $3.20
- AVG Volume (30 Days)
- LODE 1.4M
- MGNX 617.2K
- Earning Date
- LODE 11-14-2025
- MGNX 11-04-2025
- Dividend Yield
- LODE N/A
- MGNX N/A
- EPS Growth
- LODE N/A
- MGNX N/A
- EPS
- LODE N/A
- MGNX N/A
- Revenue
- LODE $3,280,749.00
- MGNX $165,495,000.00
- Revenue This Year
- LODE $7.65
- MGNX N/A
- Revenue Next Year
- LODE $1,093.72
- MGNX N/A
- P/E Ratio
- LODE N/A
- MGNX N/A
- Revenue Growth
- LODE 58.55
- MGNX 303.47
- 52 Week Low
- LODE $1.67
- MGNX $0.99
- 52 Week High
- LODE $10.10
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- LODE 63.37
- MGNX 52.37
- Support Level
- LODE $3.48
- MGNX $1.69
- Resistance Level
- LODE $3.84
- MGNX $1.83
- Average True Range (ATR)
- LODE 0.25
- MGNX 0.11
- MACD
- LODE 0.01
- MGNX 0.01
- Stochastic Oscillator
- LODE 61.71
- MGNX 64.00
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.